Patent information
IP India · live recordAbstract
MENINGOCOCCAL HEXAVALENT COMBINATION VACCINE The present invention relates to biopharmaceuticals. The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.
Applicants
1Inventors
4Claims
4Specification
Show full textCollapse
We Claim: 1. A hexavalent combination vaccine comprising (a) a combination of polysaccharidecarrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis; and (b) one or more proteins of serogroup B of N. meningitidis. 2. The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein selected from diphtheria toxoid, CRM197, tetanus toxoid, pertussis toxoid, E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa, Bacterial outer membrane proteins such as, outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysis, pneumococcal surface protein A (PspA), or pneumococcal adhesin protein (PsaA). 3. The hexavalent combination vaccine as claimed in claim 1, wherein the carrier protein is individually conjugated to the polysaccharides of serogroups A, C, Y, W and X. 4. A method of preparing the polysaccharide-carrier protein glycoconjugates of serogroups A, C, Y, W, and X of Neisseria meningitidis as claimed in anyone of claims 1-3 comprises the steps of: a) cultivating meningitis serogroup strains A, C, Y, W and X in presence of complex media for about 12–20 hours to produce meningococcal A, C, Y, W, and X polysaccharides; b) purifying the meningococcal A, C, Y, W, and X polysaccharides by processes selected from ultrafiltration, cetyl-trimethylammonium bromide (CTAB) precipitation, centrifugation, depth filtration, ethanol, and salt precipitation; c) activating each of the purified meningococcal A, C, Y, W, and X polysaccharides at an alkaline pH of 8.5–9.5 in the presence of 1-Cyano -4 Dimethylaminopyridine Tetrafluoroborate (CDAP) and at a temperature ranging from 8-15 oC; d) activating or derivatizing the carrier protein by 1-ethyl-3-(dimethylaminopropyl)-carbodiimide (EDAC) for about 16–24 hours; e) mixing and conjugating the activated A, C, Y, W, and X polysaccharides and the activated carrier proteins to obtain the polysaccharide-carrier protein glycoco
Documents
Sign in to openERegister / renewals
InforceNo renewals recorded.